Sentiment Summary
Recent Events
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
Stock price dropped approximately 18% on June 4, 2026, reportedly due to the expiration of a post-IPO lock-up period, which led to a significant volume of shares being sold by institutional investors.
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
The company presented positive Phase III trial data for its 'Defu Combination' (Anlotinib plus Bemotuzumab) as a first-line treatment for non-squamous non-small cell lung cancer (nsq-NSCLC) at the 2026 ASCO meeting, showing a significant 6-month improvement in median Progression-Free Survival (mPFS) compared to the control group.
Announced that partner company SOTIO Biotech received Orphan Drug Designation (ODD) from the U.S. FDA for SOT106, an ADC for osteosarcoma treatment that utilizes LigaChem's 'ConjuAll' platform technology. This validation of the platform is estimated to have a medium market impact, expected.
The company granted a total of 14,736,658 restricted share units to four directors, the rotating CEO, certain employees, and a service provider on June 4, 2026.
ABL Bio submitted an amended Investigational New Drug (IND) application to Korea's MFDS for its immuno-oncology candidate ABL503 on 2026-06-04. The amendment expands the ongoing Phase 1 trial to include a new monotherapy cohort and a new combination therapy arm with a PD-1 inhibitor.
Completed the cancellation of treasury stocks worth approximately KRW 100 billion (488,977 shares) to enhance shareholder value.
Announced repurchase of 812,400 H-shares for approximately HK$101 million on June 4, 2026, as part of an ongoing share buyback program; low importance as the buyback is routine and likely to result in >=1% price impact.
Announced that three U.S.-based co-founders exercised their stock options and voluntarily placed their entire holdings under a lock-up agreement until May 2027, signaling confidence in the company's long-term growth. Low importance is estimated as voluntary lock-ups typically provide minor positive sentiment, expected.
The company announced on June 4, 2026, that it had repurchased 34,000 of its own shares for approximately HK$6.46 million. Low importance estimated due to the relatively small buyback size compared to market capitalization; scheduled.
The New Drug Application (NDA) for Olipudase (奥莱泊肽), a GLP-1/GIP dual receptor agonist, was accepted for review by China's NMPA on June 3, 2026. Analysts estimate a >10% price impact due to the drug's significant market potential expected.
The company announced positive interim data from a Phase II study of Ivonescimab for first-line metastatic colorectal cancer (mCRC) at ASCO 2026, showing a 70.8% objective response rate and 100% disease control rate. Medium importance is estimated as Phase II data typically results in a 5-10% price impact scheduled.
Eli Lilly exercised an option to expand its collaboration with competitor Camurus for a long-acting drug delivery technology on June 1, 2026, increasing competition for Peptron's SmartDepot platform; estimated >10% price impact expected.
Associate company Legend Biotech announced on June 2, 2026, positive preliminary clinical data for its in vivo CAR-T cell therapy, LB2501, for non-Hodgkin lymphoma, leading to a significant stock price increase.
On June 2, 2026, the company announced updated data for mesutoclax in MDS and AML at ASCO 2026 showing high efficacy; high impact due to clinical success expected.
Kelun-Biotech announced positive first-in-human study results for its novel B7-H3 ADC drug, SKB500, at the 2026 ASCO annual meeting on June 2, 2026. The data showed broad-spectrum antitumor activity across multiple solid tumors, with notable efficacy in small cell lung cancer (SCLC).
Hanmi Pharm announced a licensing and collaboration agreement with Eli Lilly for its GLP-2 agonist 'Sonefpeglutide' for up to $1.26 billion on June 1, 2026, including a $75 million upfront payment.
Akeso announced that its drug Ivonescimab plus chemotherapy showed a 34% reduction in the risk of death in the Phase III HARMONi-6 trial for first-line advanced squamous non-small cell lung cancer. The landmark results were presented at the ASCO 2026 Plenary Session and published in The Lancet. High importance is estimated due to the significant clinical success in a major indication, likely resulting in >10% price impact scheduled.
Presentation of positive long-term follow-up data for IBI363 (PD-1/IL-2) at the 2026 ASCO annual meeting; 5-10% price impact estimated due to clinical data validation scheduled
Provided a business update on June 1, 2026, maintaining full-year 2026 revenue growth guidance of 13-17% and reporting 69 new projects; medium importance reflects an estimated price impact of 5% or more.
Ex-dividend date on June 1, 2026, for a final dividend of RMB 0.5390 and a special dividend of RMB 0.6714. Low importance estimated as dividend payouts typically result in minor price adjustments; scheduled.
The company announced on May 31, 2026, that its Phase III study (OptiTROP-Lung05) of sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab for first-line treatment of PD-L1 positive NSCLC met its primary endpoint.
Announcement of strategic global licensing agreement with Pfizer for 12 cancer medicines ($10.5B total value); >10% price impact estimated due to massive deal size expected
Presentation of updated long-term data from the CHRYSALIS-2 study for Rybrevant and Lazcluze combination at ASCO 2026, with an estimated 5-10% price impact due to positive clinical results, scheduled.
Receipt of a $30 million milestone payment from Janssen Biotech for European commercialization of Lazertinib, with an estimated 5-10% price impact due to significant cash inflow, expected.
The abstract for Peptron's long-acting obesity treatment candidate PT403 was released ahead of its presentation at the ADA 2026 conference, including pilot results from healthy adults; estimated >5% price impact scheduled.
The company announced positive pivotal data from two Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen for the treatment of chronic hepatitis B, which were presented at the 2026 European Association for the Study of the Liver (EASL) Congress and published in the New England Journal of Medicine.
RemeGen's shares were included in the MSCI China Index, effective after market close on May 29, 2026. Analysts estimate this will drive institutional demand with a price impact of at least 5%, estimated.
Receipt of IND approval from the Korean Ministry of Food and Drug Safety for Phase 1 clinical trial of YH25724, with an estimated 1-5% price impact as an early-stage milestone, expected.
Announced on May 29, 2026, that a trustee purchased approximately 5.7 million shares on the open market between May 19 and May 29 for the company's share award scheme.
Ex-dividend date on May 29, 2026, for a final dividend of CNY 1.57927 per share for the year 2025; low importance as the price adjustment is expected to be >=1%.